Immucell (ICCC) Total Non-Current Liabilities (2010 - 2026)

Immucell (ICCC) has 16 years of Total Non-Current Liabilities data on file, last reported at $11.5 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 12.69% year-over-year to $11.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.5 million (down 12.69% YoY) and the FY2025 annual result came in at $11.5 million, down 12.69% from the prior year.
• Total Non-Current Liabilities retreated to $11.5 million in Q4 2025, from $11.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $15.2 million in Q3 2023 to a low of $9.4 million in Q4 2021.
• A 5-year average of $12.0 million and a median of $11.8 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities rose 29.9% — and 2025, when it dropped 12.69%.
• Tracing ICCC's Total Non-Current Liabilities over 5 years: stood at $9.4 million in 2021, then rose by 21.96% to $11.4 million in 2022, then climbed by 28.13% to $14.6 million in 2023, then decreased by 9.9% to $13.2 million in 2024, then fell by 12.69% to $11.5 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $11.5 million (Q4 2025), $11.9 million (Q3 2025), and $12.4 million (Q2 2025), per Business Quant data.